JP6110861B2 - ワクチン療法 - Google Patents

ワクチン療法 Download PDF

Info

Publication number
JP6110861B2
JP6110861B2 JP2014532040A JP2014532040A JP6110861B2 JP 6110861 B2 JP6110861 B2 JP 6110861B2 JP 2014532040 A JP2014532040 A JP 2014532040A JP 2014532040 A JP2014532040 A JP 2014532040A JP 6110861 B2 JP6110861 B2 JP 6110861B2
Authority
JP
Japan
Prior art keywords
memory
subject
syndrome
aci
amyloid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014532040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014531455A (ja
JP2014531455A5 (enExample
Inventor
アンドリア フェイファー
アンドリア フェイファー
アンドレアス ムース
アンドレアス ムース
リメ マダニ
リメ マダニ
パーベル ワシーリエヴィチ ベリチェンコ
パーベル ワシーリエヴィチ ベリチェンコ
ウィリアム チャールズ モブリー
ウィリアム チャールズ モブリー
Original Assignee
エーシー イミューン ソシエテ アノニム
エーシー イミューン ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーシー イミューン ソシエテ アノニム, エーシー イミューン ソシエテ アノニム filed Critical エーシー イミューン ソシエテ アノニム
Publication of JP2014531455A publication Critical patent/JP2014531455A/ja
Publication of JP2014531455A5 publication Critical patent/JP2014531455A5/ja
Application granted granted Critical
Publication of JP6110861B2 publication Critical patent/JP6110861B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014532040A 2011-09-23 2012-09-21 ワクチン療法 Active JP6110861B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2011/052992 2011-09-23
USPCT/US2011/052992 2011-09-23
PCT/US2012/056728 WO2013044147A1 (en) 2011-09-23 2012-09-21 Vaccine therapy

Publications (3)

Publication Number Publication Date
JP2014531455A JP2014531455A (ja) 2014-11-27
JP2014531455A5 JP2014531455A5 (enExample) 2015-11-12
JP6110861B2 true JP6110861B2 (ja) 2017-04-05

Family

ID=47018510

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014532040A Active JP6110861B2 (ja) 2011-09-23 2012-09-21 ワクチン療法

Country Status (23)

Country Link
US (1) US20240270829A1 (enExample)
EP (1) EP2758071B1 (enExample)
JP (1) JP6110861B2 (enExample)
KR (3) KR102129220B1 (enExample)
CN (2) CN104039346A (enExample)
AU (1) AU2012312126B2 (enExample)
BR (1) BR112014006871A2 (enExample)
CA (1) CA2811188C (enExample)
DK (1) DK2758071T3 (enExample)
EA (1) EA032494B1 (enExample)
ES (1) ES2712951T3 (enExample)
HU (1) HUE041277T2 (enExample)
IL (1) IL231564A0 (enExample)
MX (1) MX350928B (enExample)
MY (1) MY169574A (enExample)
PH (1) PH12014500657A1 (enExample)
PL (1) PL2758071T3 (enExample)
PT (1) PT2758071T (enExample)
SG (1) SG11201400795UA (enExample)
SI (1) SI2758071T1 (enExample)
TR (1) TR201901846T4 (enExample)
WO (1) WO2013044147A1 (enExample)
ZA (1) ZA201402071B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
SG11202112329RA (en) * 2019-05-21 2021-12-30 Ac Immune Sa Anti-abeta vaccine therapy
KR20250137159A (ko) 2023-01-26 2025-09-17 에이씨 이뮨 에스에이 항-a베타 백신 요법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9811401A (pt) 1997-08-28 2000-08-29 Ajay North America E Som Iodo Processos para proteger uma substância agrìcola contra pestes que são nocivas para a substância agrìcola e para a proteção de uma substãncia agrìcola, e, composição protetora para substâncias agrìcolas
AU2003292936A1 (en) 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
NZ567324A (en) * 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
JP4696079B2 (ja) * 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
MX2007000998A (es) * 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
KR101152557B1 (ko) * 2005-12-12 2012-09-07 에이씨 이뮨 에스.에이. 치료 백신
NZ581835A (en) * 2007-06-12 2012-09-28 Ac Immune Sa Monoclonal anti beta amyloid antibody
HUE055739T2 (hu) * 2009-03-18 2021-12-28 Ac Immune Sa Eljárás terápiás alkalmazásra

Also Published As

Publication number Publication date
JP2014531455A (ja) 2014-11-27
KR20160005380A (ko) 2016-01-15
MX2014003325A (es) 2014-05-21
NZ622653A (en) 2015-12-24
HUE041277T2 (hu) 2019-05-28
KR20190035948A (ko) 2019-04-03
PT2758071T (pt) 2019-01-11
PL2758071T3 (pl) 2019-08-30
TR201901846T4 (tr) 2019-03-21
AU2012312126B2 (en) 2016-11-10
ES2712951T3 (es) 2019-05-16
AU2012312126A1 (en) 2014-03-27
EP2758071A1 (en) 2014-07-30
MX350928B (es) 2017-09-26
DK2758071T3 (en) 2019-02-18
WO2013044147A1 (en) 2013-03-28
IL231564A0 (en) 2014-04-30
CA2811188C (en) 2020-04-28
KR102129220B1 (ko) 2020-07-02
CN104039346A (zh) 2014-09-10
EA201400376A1 (ru) 2014-09-30
ZA201402071B (en) 2017-08-30
US20240270829A1 (en) 2024-08-15
EA032494B1 (ru) 2019-06-28
CA2811188A1 (en) 2013-03-23
SI2758071T1 (sl) 2019-01-31
EP2758071B1 (en) 2018-11-28
KR20160099732A (ko) 2016-08-22
MY169574A (en) 2019-04-22
BR112014006871A2 (pt) 2017-04-04
SG11201400795UA (en) 2014-10-30
PH12014500657A1 (en) 2014-05-05
CN109847058A (zh) 2019-06-07

Similar Documents

Publication Publication Date Title
US20240270829A1 (en) Vaccine Therapy
US7772375B2 (en) Monoclonal antibodies that recognize epitopes of amyloid-beta
AU2008267037B2 (en) Monoclonal anti beta amyloid antibody
US9585956B2 (en) Polynucleotides encoding anti-amyloid beta monoclonal antibodies
CN101883790B (zh) 抗淀粉样蛋白β抗体在眼病中的用途
US9146244B2 (en) Polynucleotides encoding an anti-beta-amyloid monoclonal antibody
JP2011251964A (ja) 超分子コンストラクトを含む方法および組成物
US20140314837A1 (en) Vaccine Therapy
NZ622653B2 (en) Vaccine therapy for the treatment of memory and/or cognitive impairments in subjects with down’s syndrome
HK1197732B (en) Vaccine therapy
HK1197732A (en) Vaccine therapy

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160819

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170118

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170310

R150 Certificate of patent or registration of utility model

Ref document number: 6110861

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250